Key facts
- It has raised $28.9M; the latest was Early Stage VC ($13.9M) in Jul 2025.
- Notable investors include The Chinese Academy of Sciences Venture Capital Management, Yijin Capital, 3Sbio, Beijing FOF Capital, Chengyi Capital (Nanjing) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Enkai Cell Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Enkai Cell Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enkai Cell Technology
Researcher of immune cell drugs designed for tumour patients. The company focuses on applying synthetic immunology technology to NK (Natural Killer) cells to artificially create various NK cells that meet different clinical needs, enabling tumour patients to get efficient treatment with fewer side effects.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 60
- Website
- nk-celltech.com/
- Ownership
- Privately Held (backing)
Enkai Cell Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enkai Cell Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enkai Cell Technology in its N-PORT filings yet. We sweep new filings monthly.